Who owns CytomX Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of CTMX from SEC Form 13F filings across 194 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 194 institutions disclosed 216.1M shares of CytomX Therapeutics, Inc. worth $587.9M — about 98.6% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
194
13F holders
$587.9M
value, 2026 filers
98.6%
of shares outstanding (216.1M sh)
41
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of CTMX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 34.3M | $93.4M | 0.0% | 15.7% | +5.0% |
| 2 | Kynam Capital Management, LP | 21.1M | $57.5M | 3.2% | 9.6% | -2.6% |
| 3 | BlackRock, Inc. | 18.5M | $50.2M | 0.0% | 8.4% | +5.2% |
| 4 | BANK OF AMERICA CORP /DE/ | 11.6M | $31.5M | 0.0% | 5.3% | -23.3% |
| 5 | PERCEPTIVE ADVISORS LLC | 9.3M | $25.2M | 0.4% | 4.2% | -11.2% |
| 6 | STATE STREET CORP | 9.0M | $24.6M | 0.0% | 4.1% | -23.2% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 8.7M | $23.8M | 0.0% | 4% | +2.4% |
| 8 | Point72 Asset Management, L.P. | 8.6M | $23.4M | 0.0% | 3.9% | +10.2% |
| 9 | CITADEL ADVISORS LLC | 7.0M | $19.1M | 0.0% | 3.2% | +125.4% |
| 10 | TWO SIGMA INVESTMENTS, LP | 5.4M | $14.6M | 0.0% | 2.5% | +30.3% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 5.1M | $13.9M | 0.0% | 2.3% | +8.9% |
| 12 | BAKER BROS. ADVISORS LP | 5.0M | $13.5M | 0.1% | 2.3% | 0.0% |
| 13 | WELLINGTON MANAGEMENT GROUP LLP | 4.7M | $12.9M | 0.0% | 2.2% | -8.5% |
| 14 | Elmind Capital, LP | 4.5M | $12.4M | 3.1% | 2.1% | 0.0% |
| 15 | Nextech Invest Ltd. | 4.4M | $12.1M | 0.5% | 2% | 0.0% |
| 16 | MARSHALL WACE, LLP | 4.4M | $11.9M | 0.0% | 2% | +44.3% |
| 17 | Qube Research & Technologies Ltd | 4.2M | $11.4M | 0.0% | 1.9% | +129.5% |
| 18 | Eversept Partners, LP | 3.5M | $9.6M | 0.5% | 1.6% | -0.4% |
| 19 | Siren, L.L.C. | 3.5M | $9.4M | 0.2% | 1.6% | 0.0% |
| 20 | UBS Group AG | 3.4M | $9.3M | 0.0% | 1.6% | -0.9% |
| 21 | GOLDMAN SACHS GROUP INC | 3.2M | $8.7M | 0.0% | 1.5% | +59.5% |
| 22 | ADAR1 Capital Management, LLC | 2.2M | $6.0M | 0.3% | 1% | -34.5% |
| 23 | Woodline Partners LP | 2.1M | $5.6M | 0.0% | 0.9% | +1.1% |
| 24 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.1M | $5.6M | 0.0% | 0.9% | +17.4% |
| 25 | NORTHERN TRUST CORP | 1.7M | $4.7M | 0.0% | 0.8% | +4.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.